Ultevursen for Vision Impairments
This trial will test if a new treatment for Retinitis Pigmentosa is safe and effective.
- Eye Diseases
- Usher Syndrome
- Vision Impairment
- Retinitis Pigmentosa
- Genetic Disorders
- Retinal Disease
- Congenital Eye Disorders
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Can new patients sign up for this clinical trial?
"Unfortunately, this specific study is not recruiting at the moment. According to clinicaltrials.gov, it was last edited on September 15th, 2022 and originally posted December 8th, 2021. There are 1258 other trials that may be of interest and are currently looking for patients."
How many different hospitals or research facilities are conducting this experiment?
"Patients are being accepted at 11 different locations for this clinical trial. Some of these sites include Columbia University in New York, New York, Shiley Eye Institute - UC San Diego in San Diego, California, and University of California, San Francisco in San Francisco, Florida."
What are the goals that this clinical trial is hoping to achieve?
"The primary goal of this experiment, which will be conducted over the course of 18 months and pit treatment against a sham procedure, is to evaluate changes in BCVA from baseline. Additionally, we will also be looking at Cmax of ultevursen in serum, change from baseline in ellipsoid zone (EZ) area and width as imaged by spectral domain optical coherence tomography (SD-OCT), and exposure of QR-421a in serum."